Neoleukin Therapeutics (NASDAQ:NLTX) and Tonix Pharmaceuticals (NASDAQ:TNXP) Financial Contrast

Tonix Pharmaceuticals (NASDAQ:TNXP) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Earnings and Valuation

This table compares Tonix Pharmaceuticals and Neoleukin Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$7.77 million	5.65	-$116.66 million	($52.74)	0.00
Neoleukin Therapeutics	N/A	N/A	-$57.56 million	($3.11)	-5.75

Neoleukin Therapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Tonix Pharmaceuticals and Neoleukin Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-1,197.86%	-163.95%	-118.88%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Tonix Pharmaceuticals and Neoleukin Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	0	0	2	0	3.00
Neoleukin Therapeutics	0	0	0	0	0.00

Tonix Pharmaceuticals presently has a consensus price target of $53.50, suggesting a potential upside of 22,665.96%. Given Tonix Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Tonix Pharmaceuticals is more favorable than Neoleukin Therapeutics.

Volatility and Risk

Tonix Pharmaceuticals has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Summary

Tonix Pharmaceuticals beats Neoleukin Therapeutics on 7 of the 13 factors compared between the two stocks.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company’s rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

About Neoleukin Therapeutics

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.